轴性脊柱关节炎患者启动非甾体抗炎药或生物制剂改善病情抗风湿药时间的性别差异
基于2013至2018年IBM MarketScan数据库174632例轴性脊柱关节炎患者,评估诊断至首次处方非甾体抗炎药或生物制剂改善病情抗风湿药的时间性别差异;女性启动非甾体抗炎药更早(aHR 1.14,95%CI 1.11-1.16),但启动生物制剂改善病情抗风湿药更晚(aHR 0.61,95%CI 0.52-0.72)。
要点
- 女性患者启动非甾体抗炎药较男性更早(aHR 1.14,95%CI 1.11-1.16)。
- 女性患者启动生物制剂改善病情抗风湿药较男性更晚(aHR 0.61,95%CI 0.52-0.72)。
- 基线期接受非甾体抗炎药者中仅4.2%启动生物制剂改善病情抗风湿药,77.9%继续非甾体抗炎药。
核心结论
- 新诊断轴性脊柱关节炎患者中处方非甾体抗炎药接收比启动生物制剂改善病情抗风湿药更常见。
- 女性患者似乎更可能在诊断后继续接收非甾体抗炎药,且启动生物制剂改善病情抗风湿药的时间较男性更长。
研究设计与样本
- 使用2013至2018年IBM MarketScan数据库识别174632例年龄≥18岁的轴性脊柱关节炎患者。
- 评估从轴性脊柱关节炎诊断至首次处方非甾体抗炎药配药(基线未接收非甾体抗炎药者)或生物制剂改善病情抗风湿药输注/操作索赔(基线期配药两种及以上不同处方非甾体抗炎药者)的时间。
- 采用生存分析计算启动非甾体抗炎药或生物制剂改善病情抗风湿药的调整风险比(aHR),并用Cox比例风险模型估计性别与治疗启动预测因素之间的关联。
主要发现
- 诊断时平均年龄48.2岁,女性占65.7%,37.8%在轴性脊柱关节炎诊断前配药一种及以上非甾体抗炎药。
- 在诊断前未接收两种及以上不同处方非甾体抗炎药者中,女性患者非甾体抗炎药接收启动较早(非甾体抗炎药接收启动者:女性32.9%,男性29.3%;aHR 1.14,95%CI 1.11-1.16)。
- 在基线期接收两种及以上不同处方非甾体抗炎药者中,4.2%接收生物制剂改善病情抗风湿药,而77.9%在诊断后继续接收非甾体抗炎药。
- 女性患者启动生物制剂改善病情抗风湿药接收的时间较男性更长(aHR 0.61,95%CI 0.52-0.72),但在基线期接收非甾体抗炎药者中生物制剂改善病情抗风湿药接收更早。
关键数值与推荐
- 女性患者启动非甾体抗炎药接收的aHR为1.14(95%CI 1.11-1.16),对象为诊断前未接收两种及以上不同处方非甾体抗炎药者。
- 女性患者启动生物制剂改善病情抗风湿药接收的aHR为0.61(95%CI 0.52-0.72),对象为基线期接收两种及以上不同处方非甾体抗炎药者。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: We evaluated sex differences in time to initiation of receiving nonsteroidal anti-inflammatory drugs (NSAIDs) or biologic disease-modifying antirheumatic drugs (bDMARDs) among patients with axial spondyloarthritis (axSpA). METHODS: Using the 2013 to 2018 IBM MarketScan Database, we identified 174,632 patients with axSpA aged ≥18 years. We evaluated the time between axSpA diagnosis and the first prescription NSAID dispensing (among those with no baseline NSAIDs reception) or bDMARDs infusion/procedure claim (among those who were dispensed two or more different prescription NSAIDs in the baseline period). Adjusted hazard ratios (aHRs) for time to initiation of patients receiving NSAIDs or bDMARDs were computed using survival analyses. Cox proportional hazard models estimated associations between sex and predictors of treatment initiation. RESULTS: Average age at diagnosis was 48.2 years, 65.7% were female, and 37.8% were dispensed one or more NSAIDs before axSpA diagnosis. Of those who did not receive two or more different prescription NSAIDs before diagnosis, NSAID reception was initiated earlier in female patients than in male patients (NSAID reception initiators: female patients (32.9%), male patients (29.3%); aHR 1.14, 95% confidence interval [CI] 1.11-1.16). Among those who received two or more different prescription NSAIDs in the baseline period, 4.2% received a bDMARD, whereas 77.9% continued receiving NSAIDs after diagnosis. Time to bDMARD reception initiation was longer for female patients than for male patients (aHR 0.61, 95% CI 0.52-0.72), but bDMARDs were received sooner among those who received NSAIDs in the baseline period. CONCLUSION: Prescription NSAID reception was more common than initiation of receiving bDMARDs among patients newly diagnosed with axSpA. Female patients appeared more likely to continue receiving NSAIDs after diagnosis, and the time to initiation of receiving bDMARDs was longer for female patients than for male patients.
引用
- Shridharmurthy D, Lapane KL, Baek J, et al. Sex Differences in Time to Initiate Nonsteroidal Anti-Inflammatory Drugs or Biologic Disease-Modifying Antirheumatic Drugs Among Patients With Axial Spondyloarthritis. Arthritis Care Res (Hoboken). 2024. PMID: 38538532. doi:10.1002/acr.25332
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。